Tounjian Advisory Partners’s Zenas BioPharma ZBIO Stock Holding History

Tounjian Advisory Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.5K	Buy	+2,500	New	+$49.7K	0.03%	212

Other funds holding ZBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Tounjian Advisory Partners's ZBIO Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 2,500 shares worth $63.5K. The stake represents 0.03% of the portfolio and ranks #212 among its holdings.

42 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Tounjian Advisory Partners held 2,500 shares of Zenas BioPharma worth $63.5K as of Q2 2026.
Zenas BioPharma was a new Tounjian Advisory Partners position in Q2 2026.
Zenas BioPharma made up 0.03% of Tounjian Advisory Partners's portfolio in Q2 2026, its #212 holding.
42 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.